Yi Kan Wang
Research Subjects
Yi Kan Wang has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Adam Casson
Paige AI, New York, New York. 2
3 shared publications - Andrea Gazzo
Agostino Gemelli University Polyclinic 5
3 shared publications - Anton Safonov
Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut
3 shared publications - Antonio Marra
Department of Oncology and Hemato-Oncology, University of Milano La Statale, Milan, Italy
3 shared publications - Arnaud Da Cruz Paula
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
3 shared publications - Brandon Rothrock
Paige AI, New York, New York. 2
3 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A Genomics-Driven Artificial Intelligence–Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms
Supplementary Figures S1-S5 Supplementary Tables S1-S5
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A Genomics-Driven Artificial Intelligence–Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms
Supplementary Figures S1-S5 Supplementary Tables S1-S5
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A Genomics-Driven Artificial Intelligence–Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms
Supplementary Figures S1-S5 Supplementary Tables S1-S5
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A Genomics-Driven Artificial Intelligence–Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms
Supplementary Figures S1-S5 Supplementary Tables S1-S5
- 6 August 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (20) , 3478-3489
A Genomics-Driven Artificial Intelligence – Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms
Artificial intelligence (AI) systems can improve cancer diagnosis, yet their development often relies on subjective histologic features as ground truth for training. Herein, we developed an AI model applied to histologic whole-slide images using CDH1 biallelic mutations, pathognomonic for invasive lobular carcinoma (ILC) in breast neoplasms, as ground truth. The model accurately predicted CDH1 biallelic mutations (accuracy = 0.95) and diagnosed ILC (accuracy = 0.96). A total of 74% of samples classified by the AI model as having CDH1 biallelic mutations but lacking these alterations displayed alternative CDH1 inactivating mechanisms, including a deleterious CDH1 fusion gene and noncoding CDH1 genetic alterations. Analysis of internal and external validation cohorts demonstrated 0.95 and 0.89 accuracy for ILC diagnosis, respectively. The latent features of the AI model correlated with human-explainable histopathologic features. Taken together, this study reports the construction of an AI algorithm trained using a genetic rather than histologic ground truth that can robustly classify ILCs and uncover CDH1 inactivating mechanisms, providing the basis for orthogonal ground truth utilization for development of diagnostic AI models applied to whole-slide image. Significance: Genetic alterations linked to strong genotypic–phenotypic correlations can be utilized to develop AI systems applied to pathology that facilitate cancer diagnosis and biologic discoveries.
- 6 August 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (20) , 3478-3489
A Genomics-Driven Artificial Intelligence – Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms
Artificial intelligence (AI) systems can improve cancer diagnosis, yet their development often relies on subjective histologic features as ground truth for training. Herein, we developed an AI model applied to histologic whole-slide images using CDH1 biallelic mutations, pathognomonic for invasive lobular carcinoma (ILC) in breast neoplasms, as ground truth. The model accurately predicted CDH1 biallelic mutations (accuracy = 0.95) and diagnosed ILC (accuracy = 0.96). A total of 74% of samples classified by the AI model as having CDH1 biallelic mutations but lacking these alterations displayed alternative CDH1 inactivating mechanisms, including a deleterious CDH1 fusion gene and noncoding CDH1 genetic alterations. Analysis of internal and external validation cohorts demonstrated 0.95 and 0.89 accuracy for ILC diagnosis, respectively. The latent features of the AI model correlated with human-explainable histopathologic features. Taken together, this study reports the construction of an AI algorithm trained using a genetic rather than histologic ground truth that can robustly classify ILCs and uncover CDH1 inactivating mechanisms, providing the basis for orthogonal ground truth utilization for development of diagnostic AI models applied to whole-slide image. Significance: Genetic alterations linked to strong genotypic–phenotypic correlations can be utilized to develop AI systems applied to pathology that facilitate cancer diagnosis and biologic discoveries.